TY - JOUR
T1 - Impact of obesity on clinical outcomes of methicillin-susceptible Staphylococcus aureus bloodstream infections
AU - Wasielewski, Anthony S.
AU - Casapao, Anthony M.
AU - Jankowski, Christopher A.
AU - Isache, Carmen L.
AU - Ravi, Malleswari
AU - Kunz Coyne, Ashlan J.
N1 - Publisher Copyright:
© 2024 American Society for Microbiology. All Rights Reserved.
PY - 2024/11
Y1 - 2024/11
N2 - Obesity affects over one-third of U.S. adults and complicates the treatment of methicillin-susceptible Staphylococcus aureus (MSSA) bloodstream infections (BSI). A study at the University of Florida Health Centers compared clinical outcomes between 233 obese and non-obese patients receiving cefazolin for MSSA BSI. No significant differences were found in clinical success (81.9% vs 82.7%), mortality (7.2% vs 5.3%), or adverse events (3.6% vs 3.3%). However, obese patients took longer to clear blood cultures (4.62 vs 4.01 days, P = 0.017).
AB - Obesity affects over one-third of U.S. adults and complicates the treatment of methicillin-susceptible Staphylococcus aureus (MSSA) bloodstream infections (BSI). A study at the University of Florida Health Centers compared clinical outcomes between 233 obese and non-obese patients receiving cefazolin for MSSA BSI. No significant differences were found in clinical success (81.9% vs 82.7%), mortality (7.2% vs 5.3%), or adverse events (3.6% vs 3.3%). However, obese patients took longer to clear blood cultures (4.62 vs 4.01 days, P = 0.017).
KW - cefazolin
KW - methicillin-susceptible Staphylococcus aureus
KW - obesity
UR - http://www.scopus.com/inward/record.url?scp=85208688030&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85208688030&partnerID=8YFLogxK
U2 - 10.1128/aac.00752-24
DO - 10.1128/aac.00752-24
M3 - Article
C2 - 39324801
AN - SCOPUS:85208688030
SN - 0066-4804
VL - 68
JO - Antimicrobial Agents and Chemotherapy
JF - Antimicrobial Agents and Chemotherapy
IS - 11
ER -
